ImageneBio Inc (IMA) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

ImageneBio Inc (IMA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $66.9M, listed on NASDAQ, employing roughly 10 people, carrying a beta of 0.74 to the broader market. Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis Led by Kristin Yarema, public since 1998-02-27.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for IMA as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →